Dr. Benjamin M. Solomon, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 459
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Nebraska College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
SD license 8825 -
Internal Medicine Physician
MN license 50980 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Avera Mckennan Hospital & University Health Center Sioux Falls, SD
- Avera Marshall Regional Medical Ctr Marshall, MN
- Avera St Mary's Hospital Pierre, SD
- Brookings Health System Brookings, SD
- Avera Queen of Peace Mitchell, SD
Medical groups
- Avera Mckennan (959 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 459
- Services billed
- 1,848
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 597 | 319 |
| Established patient office or other outpatient visit, 40-54 minutes | 245 | 128 |
| Established patient office or other outpatient visit, 20-29 minutes | 178 | 148 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 56 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 38 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 36 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 17 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Sioux Falls, SD | 81 |
| Eliquis (apixaban) Other prescribers in Sioux Falls, SD | 52 |
| Xtandi (enzalutamide) | 46 |
| Abiraterone Acetate | 44 |
| Gabapentin Other prescribers in Sioux Falls, SD | 43 |
| Levothyroxine Sodium Other prescribers in Sioux Falls, SD | 28 |
| Tagrisso (osimertinib mesylate) | 27 |
| Prochlorperazine Maleate Other prescribers in Sioux Falls, SD | 26 |
| Inlyta (axitinib) | 23 |
| Imbruvica (ibrutinib) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 8 payments worth $327 in total to this clinician.
| Tempus Ai, Inc | $120 |
|---|---|
| Pfizer Inc. | $78.00 |
| Celgene Corporation | $65.40 |
| Beone Medicines USA, Inc. | $29.09 |
| AstraZeneca Pharmaceuticals LP | $20.40 |
| Daiichi Sankyo Inc. | $14.27 |
| Food and Beverage | $249 |
|---|---|
| Education | $78.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 21, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
| Pfizer Inc. May 6, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
| Pfizer Inc. Jul 29, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 11 companies. The companies reported $1,451,378 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Amgen Inc. - A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)
Amgen Inc. - A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen Inc. - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non …
AstraZeneca Pharmaceuticals LP - A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-sm…
AstraZeneca Pharmaceuticals LP - Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer
AstraZeneca Pharmaceuticals LP - An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizu…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.